MRNA - Moderna Will Revolutionize Cancer Vaccines With Intismeran and Merck. But the market has already priced in a lot of success
Moderna is transitioning from a COVID-vaccine company to a cancer-vaccine company, with its intismeran cancer vaccine (developed with Merck) showing promise, particularly in melanoma. While this new therapy offers significant market potential, the stock's substantial increase from $24 to $203 suggests that much of this success is already factored into its current price. Risks include regulatory hurdles, the full efficacy data not yet being released for Phase 3 trials, competition from BioNTech, and ongoing cash burn.
Eisai and Biogen Present Clarity AD Analysis Showing Lecanemab Slows Decline in Early Alzheimer’s Disease Patients With α-Synuclein Co-Pathology
Eisai Co., Ltd. and Biogen Inc. presented new findings at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, showing that lecanemab (LEQEMBI®) significantly slowed clinical decline in early Alzheimer’s disease patients with α-synuclein (α-Syn) co-pathology. The analysis of Clarity AD cerebrospinal fluid samples indicated that α-Syn co-pathology is more prevalent in amyloid beta-positive participants and that lecanemab treatment reduced clinical deterioration in α-Syn-positive patients over 18 months. These results suggest a robust clinical benefit for individuals with this co-pathology, deepening the understanding of the disease and expanding lecanemab's potential therapeutic scope.
Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. announced new findings from an analysis of lecanemab treatment and α-synuclein (α-Syn) co-pathology in the Clarity AD CSF substudy for early Alzheimer’s disease. The data, presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, indicate that lecanemab slowed clinical decline in both the overall α-Syn-tested group and the α-Syn-positive subgroup, which is typically associated with higher amyloid burden and faster disease progression. These results suggest that lecanemab offers clinical benefits even to individuals with α-Syn co-pathology, a factor that can contribute to disease heterogeneity and progression.
PRISM MarketView Highlights Four Small Caps Working on Alzheimer’s...
PRISM MarketView published a feature on four small-cap companies—Annovis Bio (ANVS), AC Immune (ACIU), IGC Pharma (IGC), and Firefly Neuroscience (AIFF)—focusing on their progress in Alzheimer's disease research, timed with the CTAD 2026 conference. The article provides updates on each company's clinical trials, including expected timelines and key findings, emphasizing the promotional nature of the PRISM MarketView piece rather than new data disclosure. Shareholder-relevant information includes Annovis's continued Phase 3 trial, AC Immune's positive antibody responses, IGC Pharma's completed dosing, and Firefly's EEG system adoption.
Align Technology Appoints Paul Clancy and Ian Bell to Board
Align Technology (Nasdaq: ALGN) has announced the appointment of Paul J. Clancy and Ian Bell to its Board of Directors. Clancy, a biopharmaceutical executive and former CFO of Alexion Pharmaceuticals and Biogen Inc., is effective immediately, while Bell, Senior Vice President and COO of Alcon Inc., will join on December 10, 2026. These appointments are expected to enhance the board's expertise in global healthcare, finance, innovation, and operations, contributing to Align's strategic execution and long-term growth.
H.C. Wainwright reiterates Buy rating on Biogen stock at $270
H.C. Wainwright has reiterated a Buy rating on Biogen Inc. with a $270 price target, following the presentation of positive Phase 2 CELIA study data for its drug diranersen at CTAD 2026. The data indicated that diranersen's benefits deepened with longer treatment, particularly in slowing cognitive decline and reducing a key Alzheimer's biomarker. The analyst firm highlighted the drug's combination potential with anti-amyloid approaches and noted that the 60 mg twice-yearly dose showed consistent effects and good tolerability, making it a likely candidate for Phase 3.
Align Technology appoints Paul J Clancy, Ian Bell to its board
Align Technology, Inc. has announced the appointment of Paul J. Clancy and Ian Bell to its Board of Directors. Clancy, a biopharmaceutical executive, joined immediately, while Bell, Senior Vice President and COO of Alcon Inc., will join on December 10, 2026. These appointments aim to leverage their extensive global healthcare, financial, innovation, and operational leadership experience to support Align's strategic execution and long-term growth.
Valion Bio names former Army official and biotech CEO as advisor
Valion Bio, Inc. has appointed Armand Balboni, JD, MD, PhD, as an advisor to lead its scientific strategy and medical countermeasure development, particularly for its lead candidate, Entolimod. Dr. Balboni's extensive background includes serving as CEO of Appili Therapeutics Inc. and 24 years of military service with the U.S. Army, where he oversaw FDA-regulated clinical trials. His expertise will be crucial in advancing Entolimod, which has Fast Track and Orphan Drug designations, through government and strategic partnerships.
Biopharma Co. Targeting Alzheimer's Disease Process, Not Just Symptoms
Cognition Therapeutics Inc. (CGTX) is developing an oral drug, zervimesine (CT1812), aimed at protecting brain cell connections from damage associated with Alzheimer's disease by preventing toxic amyloid-beta oligomers from binding to synapses. The company is presenting research on plasma p-tau217 screening in its Phase 2 START Alzheimer's trial, which is expected to yield topline results in H2 2027. Additionally, Cognition Therapeutics plans to initiate a Phase 3 program for dementia with Lewy body psychosis in mid-2027, following positive Phase 2 results.
RCS - Hutchmed China Ltd - China NMPA Approval of SYVIK
HUTCHMED (China) Limited announced that China's NMPA has simultaneously approved two New Drug Applications for SYVIK® (sovleplenib) for the treatment of adult patients with chronic primary Immune Thrombocytopenia (ITP) and Warm Antibody Autoimmune Hemolytic Anemia (wAIHA). SYVIK® is the first novel Syk inhibitor approved in China, marking HUTCHMED's expansion into immunology beyond oncology. The approvals are supported by positive Phase III ESLIM-01 trial data for ITP and Phase II/III ESLIM-02 trial data for wAIHA, demonstrating significant efficacy and a tolerable safety profile.
Nio Deepens Decade-Long Paint Deal With Carlyle-Backed Supplier
Nio has extended its long-standing supply relationship with Surventis, previously BASF Coatings, through a new strategic cooperation letter of intent. This agreement deepens their collaboration on vehicle coatings for Nio, Onvo, and Firefly brands, including color design, sustainability solutions, and joint development of new coating materials. The partnership, which began with Nio's first model in 2018, builds on a previous 2025 agreement and highlights Surventis's continued support as an independent company.
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
AbbVie has agreed to a deal with Germany's Disco Pharmaceuticals worth up to $2.54 billion to develop next-generation bispecific cancer therapies. This collaboration focuses on "AND-gated" bispecific therapeutics for solid tumors, designed to target cancer cells more precisely by requiring the simultaneous presence of two target proteins. Disco will handle research and discovery, with AbbVie having exclusive licensing rights for further development.
Biogen to Participate in December Healthcare Conferences
Biogen Inc. announced that Alisha Alaimo, President, Head of North America, will participate in a fireside chat at the Evercore 9th Annual Healthcare Conference on November 30, 2026, at 1:20 p.m. ET. Additionally, Anchal Joshi, Product Development and Commercialization Lead, Nephrology, will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on December 3, 2026, at 9:30 a.m. ET. Webcasts for both events will be available on Biogen’s investor relations website.
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco
AbbVie has agreed to a deal worth up to $2.54 billion with Germany's Disco Pharmaceuticals to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, plus royalties, for its AND-gated bispecific therapeutics. This early-stage partnership aims to create treatments that specifically target cancer cells by requiring two proteins to be present simultaneously, thereby potentially reducing harm to healthy tissue.
US FDA approves Regeneron’s drug for generalized myasthenia gravis
The US FDA has approved Regeneron Pharmaceuticals' drug, Livsayis (cemdisiran), for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. Livsayis is an RNA-silencing therapy administered quarterly, marking Regeneron's first approved medicine in both siRNA and neurology fields. The drug carries a boxed warning for meningococcal infections, requiring vaccination before treatment.
Biogen’s Tau-Targeting Diranersen Shows Continued Alzheimer’s Efficacy At Two Years
Biogen's diranersen, an Ionis-partnered tau-targeting antisense oligonucleotide, demonstrated continued efficacy in early Alzheimer's disease patients over two years in its Phase II CELIA trial, despite missing the primary endpoint. The lowest dose showed improved effects on cognition, function, and disease progression at 96 weeks compared to 76 weeks, supporting its advancement to Phase III development.
Biogen's tau-targeting Alzheimer's drug showed 38% slower decline after two years—but the data weren't randomized
Biogen reported that its experimental tau-lowering Alzheimer's drug, diranersen, slowed cognitive decline by 38% after two years in a low-dose group, according to open-label extension data. While these results suggest a potential new target for Alzheimer's treatment, the findings are not from a randomized, placebo-controlled trial and thus do not constitute approved treatment evidence. The drug is not yet approved and Biogen plans a Phase 3 trial to confirm efficacy and safety.
Align Technology appoints two directors to board By Investing.com
Align Technology Inc. (NASDAQ:ALGN) has appointed Paul J. Clancy and Ian Bell to its Board of Directors. Clancy, with over 30 years of experience in biotech and pharma, joins immediately, while Bell, a current Senior Vice President and COO at Alcon Inc., will join on December 10, 2026. These appointments will temporarily increase the board to 13 directors before C. Raymond Larkin, Jr. retires at the end of 2026, reducing the total to 12.
Paul J. Clancy and Ian Bell to Join Align Technology Board of Directors
Align Technology, Inc. has announced the appointment of Paul J. Clancy and Ian Bell to its Board of Directors. Paul J. Clancy, a former CFO of Alexion Pharmaceuticals and Biogen, joins immediately, bringing over 30 years of strategic, financial, and operational leadership experience. Ian Bell, Senior Vice President and Chief Operating Officer of Alcon Inc., will join on December 10, 2026, contributing broad experience across commercial, manufacturing, quality, and regulatory operations.
BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
Bristol Myers Squibb (BMS) presented early data from its Phase 3 ADEPT program for Cobenfy (KarXT) at the CTAD conference, showing improvements in hallucinations and delusions in Alzheimer's disease psychosis patients. While efficacy signals were encouraging, analysts expressed concerns regarding the high rate of treatment-emergent adverse events (TEAEs) and discontinuations. The full randomized, placebo-controlled data, including relapse prevention, is expected in 2027 after previous delays.
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
At the 2026 Clinical Trials on Alzheimer’s Disease conference, Biogen and AriBio reported positive results for their Alzheimer's therapies. Biogen's anti-tau therapy, diranersen, showed a 38% slowing of clinical decline over two years, supporting its advancement to Phase 3. AriBio's PDE5 inhibitor, AR1001, achieved success in a Phase 3 trial by slowing clinical decline by 31% in a monotherapy subgroup, with plans to discuss results with the FDA.
ALGN: Align Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Align Technology Inc. has filed an SEC Form 8-K announcing the appointment of two new directors to its board: Paul Clancy, effective immediately, and Ian Bell, effective December 10, 2026. This expands the board to 13 members temporarily, before returning to 12 upon Raymond Larkin's retirement on December 31, 2026. The appointments add significant finance, strategy, and operations experience from the healthcare sector.
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. announced new three-year real-world findings from the LEADER study, showing LEQEMBI® reduced the rate of progression to moderate or severe Alzheimer's disease dementia by 76%. The study, which included 560 patients, also reported that over 80% of patients remained stable or improved and that amyloid clearance was observed in 77% of patients at sites with follow-up PET data. Safety findings were consistent with previous real-world experience, and an international meta-analysis of 5,000 patients further supported lower ARIA rates compared to clinical trials.
Biogen's Tau-Targeting Alzheimer's Drug Shows 38% Slowing of Decline at Two Years
Biogen reported new two-year Phase 2 CELIA data for its investigational tau-targeting therapy, diranersen, showing a 38% slowing of clinical decline in early Alzheimer's disease patients with the 60 mg twice-yearly dose. The benefit on CDR-SB widened over time, and the drug also showed improvements in other cognitive measures and reduced tau biomarkers. Despite missing its primary endpoint at Week 76, the growing treatment effect and biomarker reductions offer a potential path forward for Biogen's tau-directed approach in Alzheimer's treatment.
Nuvation Bio's David Hung: 90% Response Rate in ROS1 Lung Cancer Backs a China-Sourced Drug Strategy
David Hung, CEO of Nuvation Bio, discusses the success of obetrosi, a ROS1 lung cancer drug acquired through AnHeart Therapeutics, which boasts a 90% first-line response rate and a median duration of response exceeding four years. Hung emphasizes the drug's efficacy and tolerability, particularly for a younger patient demographic often presenting with brain metastases. Nuvation Bio plans to expand its pipeline through further acquisitions from Chinese labs and academic centers and is developing obetrosi for adjuvant use.
Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline
Biogen (NASDAQ:BIIB) announced that its investigational therapy, diranersen, demonstrated a slowing of clinical decline in individuals with early Alzheimer's disease over two years. The Phase 2 CELIA study data, presented at the CTAD 2026 conference, showed increasing clinical benefits across cognition, function, and disease progression, particularly with a twice-yearly 60 mg regimen. Although the study did not meet its primary endpoint, the therapy showed reductions in tau pathology and was generally well-tolerated.
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen plans to announce results from two systemic lupus erythematosus trials in early December, with results for cutaneous lupus erythematosus expected early next year. The company aims for its first annual revenue growth since 2019, driven by existing products like Leqembi, Zurzuvae, Syfovre, and Empaveli, and new pipeline developments in lupus, spinal muscular atrophy, and antibody-mediated rejection. Biogen is preparing for various launch scenarios depending on trial outcomes and regulatory approvals, expecting significant market potential in lupus.
Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
Biogen announced new two-year data from its Phase 2 CELIA study, showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy, in people with early Alzheimer's disease. The 60 mg twice-yearly regimen demonstrated the largest treatment effects, including a 38% slowing of clinical decline on CDR-SB and other measures, which increased from 18 months to two years. These findings, presented at the CTAD conference, strengthen the evidence for tau as a therapeutic target and support diranersen's potential to impact disease progression.
Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
Biogen announced new Phase 2 CELIA study data showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people with early Alzheimer's disease at two years. The 60 mg twice-yearly regimen demonstrated a 38% slowing of clinical decline on CDR-SB and greater slowing across multiple measures compared to 18 months, with a favorable benefit-risk profile. These findings support tau as a therapeutic target and the continued development of diranersen, reinforcing its potential to impact disease progression meaningfully.
Alzheimer's Brain Scan Clinic Clears Major Medicare Hurdle
Grey Matters Health Inc. has achieved accreditation and completed Medicare and Medicaid enrollment for its flagship NovaScan Neuroimaging Clinics location in Davie, Florida. This allows the clinic to provide diagnostic PET imaging services for Alzheimer's and other neurodegenerative conditions to eligible patients. The company plans to establish a national network of 100-200 brain-specific PET imaging clinics across the U.S., utilizing its FDA-cleared CareMiBrain system.
How Did AbbVie's Neuroscience Franchise Perform in Q3?
AbbVie's neuroscience segment experienced strong growth in Q3 2026, generating $3.39 billion in revenues, a 19.5% increase year-over-year. This performance, driven by drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, led AbbVie to raise its 2026 neuroscience sales outlook to $13 billion. The company also highlighted the potential of newly approved PD drug Juvmo and reiterated Vyalev's path to blockbuster status.
Biogen’s anti-tau Alzheimer’s drug benefits increase at 2 years
New trial data shows that Biogen's experimental anti-tau Alzheimer's drug, diranersen, slowed cognitive decline by 38% after two years in early Alzheimer's patients, an increase from 26% at 18 months. This lowest 60-milligram dose proved to be the most effective and well-tolerated, demonstrating the first instance of a tau-targeting drug slowing Alzheimer's progression. Biogen is now discussing Phase 3 trials with regulators and considering how diranersen could be used with other Alzheimer's treatments like Leqembi.
Biogen’s anti-tau Alzheimer’s drug benefits increase at 2 years
New trial data shows that Biogen's experimental anti-tau Alzheimer's drug, diranersen, significantly slowed cognitive decline in early Alzheimer's patients after two years. The lowest dose (60-milligram twice-yearly) improved cognitive decline by 38%, an increase from the 26% reported at 18 months, making it the first tau-targeting drug to demonstrate such efficacy. Biogen is now discussing Phase 3 trial outlines with regulators and exploring potential combination therapies with amyloid-targeting drugs like Leqembi.
SEALSQ acquires Miraex to expand quantum technology stack
SEALSQ Corp (NASDAQ: LAES) has announced the acquisition of Miraex, a photonic integrated circuit company, to advance its Quantum Sovereign Vertical Stack development. Miraex specializes in thin-film lithium tantalate photonic integrated circuits crucial for bridging microwave and optical frequencies in quantum processors. This acquisition is expected to bolster SEALSQ's "Root-to-Qubit-to-Space" architecture and Quantum Orbital Space Cloud initiative, leveraging Miraex's compact, energy-efficient, and radiation-tolerant photonic components.
The Rosen Law Firm, P.A. Announces Proposed Class Action
The Rosen Law Firm, P.A. has announced a proposed class action settlement for purchasers of publicly-traded Biogen Inc. common stock (NASDAQ: BIIB) who acquired shares between October 22, 2019, and November 5, 2020. The United States District Court for the District of Massachusetts has approved the settlement announcement, which involves a $25,000,000 fund. A Settlement Fairness Hearing is scheduled for March 5, 2027, to determine the fairness of the settlement, the plan of allocation, and attorney fees.
Teva Pharmaceutical Industries (TEVA) Could Be 13% Undervalued Following FDA Approval For IGALMI
Teva Pharmaceutical Industries recently received FDA approval for at-home use of IGALMI, a sublingual film for agitation in mental health conditions. Analysts at Simply Wall St believe the stock is 13% undervalued, with a fair value of $48.94 compared to its current trading price of $42.57. This valuation is based on expected profit growth from Teva's shift towards higher-value branded CNS drugs, though it depends on successful product launches and avoiding pipeline setbacks.
Tryngolza approved in EU for severe hypertriglyceridaemia
The European Commission has approved Tryngolza (olezarsen) for adults with severe hypertriglyceridaemia (sHTG) and fasting triglyceride levels of at least 880 mg/dL. This RNA-targeted therapy, based on data from the phase 3 CORE and CORE2 studies, significantly reduced triglyceride levels by up to 73% and acute pancreatitis events by 83%. This approval addresses an unmet need for patients at high risk of acute pancreatitis in the EU.
Lexeo’s LX2020 Earns RMAT Designation for PKP2 Cardiomyopathy
Lexeo Therapeutics' LX2020 has received RMAT designation from the FDA for PKP2 cardiomyopathy, based on positive interim data from its Phase I/II trial. This designation indicates the therapy may offer substantial improvement over existing options for this serious condition and will lead to closer FDA collaboration and a potential expedited review. The trial has successfully dosed a majority of participants at the higher, therapeutic dose level, establishing a credible safety database for regulatory discussions.
DataMEDS says patient data may help cut healthcare costs
DataMEDS AI released its fourth-quarter 2026 outlook, emphasizing GLP-1 patient management and integrating healthcare delivery with AI to improve outcomes and reduce costs. The company is collaborating with a Florida-based HMO and recently acquired Helomics to expand research and development, expecting to generate new intellectual property from patient data. DataMEDS aims to leverage patient data to streamline healthcare, eliminate middlemen, and provide a more efficient and affordable alternative for patients and payors.
FDA Approval for ZURZUVAE issued to BIOGEN
The FDA has issued an efficacy supplement (SUPPL-4) for Biogen's ZURZUVAE, expanding its approved label to include a new patient population. This is a regulatory update, not an initial approval, as the drug was originally approved in 2023. While positive for shareholders by potentially widening the drug's use, the specific new patient group and commercial benefits are not detailed in the filing.
Eisai and Biogen Report Five-Year Data Showing Sustained Benefit of Continuous Lecanemab Treatment in Early Alzheimer’s Disease
Eisai and Biogen presented five-year data at the CTAD conference showing that continuous lecanemab treatment provides sustained benefits for patients with early Alzheimer's disease. The Phase 3 Clarity AD study found that patients experienced reduced cognitive decline and a lower risk of disease progression, particularly those with low tau levels. The drug's safety profile remained consistent throughout the five-year treatment period, reinforcing its potential as a significant long-term therapy.
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. presented new five-year data on lecanemab from the Clarity AD study's long-term extension, showing continuous benefits for patients with early Alzheimer's disease. The data indicated that lecanemab reduced the relative risk of progression to the next stage of disease by 36% and that 62% of patients with low tau showed improvement in cognitive function and activities of daily living at five years. The safety profile remained consistent with no new findings over the five-year treatment period.
Weekly Recap: First-half earnings growth and Japan LEQEMBI Pen launch
Eisai Co., Ltd. (TSE:4523) reported strong first-half FY2026 results, with revenue up 17.5% and operating profit up 20.4%, driven by key products like LENVIMA, DAYVIGO, and LEQEMBI. The company maintained its full-year forecasts. Additionally, Eisai and Biogen launched the once-weekly LEQEMBI Pen in Japan, offering a self-administration option for early Alzheimer's disease.
Biogen Signs TRIMTECH Deal for Protein Degraders: Up to $411M Total, Only $32M Early
Biogen International GmbH has signed an option agreement with TRIMTECH Therapeutics for TRIM21-based protein degraders targeting neurodegenerative diseases. The deal includes up to $411 million in potential payments, with $32 million in upfront and research milestones. TRIMTECH's technology focuses on degrading clumped proteins, but the agreement primarily signals Biogen's interest in a new mechanism rather than clinical proof, as the approach still faces challenges in brain delivery and confirming the toxicity of targeted protein assemblies.
FDA Approval for ZURZUVAE issued to BIOGEN
The FDA has approved an efficacy supplement (SUPPL-4) to Biogen's ZURZUVAE application, adding a new patient population to the drug's approved label. This is a regulatory update for an already approved drug, with the original approval dating back to August 4, 2023. While the expansion could widen the drug's potential use, the specific new patient group is not disclosed, making it difficult to assess the commercial impact for shareholders.
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
Teva Pharmaceutical Industries Ltd. announced FDA approval for IGALMI (dexmedetomidine) sublingual film, making it the first at-home treatment for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. The approval follows a successful Phase 3 trial demonstrating consistent tolerability. Teva acquired worldwide rights to IGALMI from BioXcel Therapeutics in late October 2026.
Arexera Says Huntington's Drug ATL-101 Cut Huntingtin Up to 80% in Primates; Alnylam Has Human Data
Arexera Therapeutics announced that its Huntington's disease drug ATL-101 reduced huntingtin protein by up to 80% in non-human primate brain tissue and that China approved a Phase 1 trial. This primate data is company-reported and will be presented in 2027. While a promising biomarker, the results are from primate tissue and cannot be directly compared to Alnylam's human spinal fluid data for its rival drug, brezosiran, which showed a 60% to 64% average drop in patients.
Pharvaris N.V. Ransomware Attack by N0n
Pharvaris N.V., a healthcare company based in the Netherlands, has been subjected to a ransomware attack by the n0n threat group. The attack was discovered on November 16, 2026, and the n0n group has claimed responsibility. This incident is part of a broader campaign by n0n, which has targeted 205 victims across various sectors, including healthcare, since September 2026.
Verastem, Inc. Ransomware Attack by N0n
Verastem, Inc., a biopharmaceutical company, has been identified as a victim of a ransomware attack by the "n0n" group. The attack was discovered on November 16, 2026, with a 100% confidence level and medium severity. The n0n group, which has been active since September 2026, has claimed 203 victims to date and frequently targets the healthcare industry.
|‘Ahead of its peers in clinical development’: Fan on Fate Therapeutics
Martin Fan, Vice President of Equity Research at Wedbush, discussed Fate Therapeutics as one of his top picks in the biotech sector. He highlighted the company's advanced position in clinical development compared to its competitors. This interview took place on BNN Bloomberg, where Fan shared his insights on promising biotech investments.